A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors

Cell Reports

Volumn 13, Issue 11, 2015, Pages 2376-2385

  Kao, Daniela ^a   Danzer, Heike ^a   Collin, Mattias ^b   Groß, Andrea ^a   Eichler, Jutta ^a   Stambuk, Jerko ^c   Lauc, Gordan ^c   Lux, Anja ^a   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

Author keywords

Cytotoxic antibodies; Fc receptors; Glycosylation; IgG

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2C; IMMUNOGLOBULIN G3; MONOSACCHARIDE; UNCLASSIFIED DRUG; CD20 ANTIGEN; COMPLEMENT COMPONENT C1Q; FCGR1 PROTEIN, MOUSE; GLYCOPEPTIDASE; GLYCOPEPTIDE; GLYCOSIDASE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; CHO CELL LINE; CRICETULUS; CYTOLOGY; DEFICIENCY; GENETICS; GLYCOSYLATION; HAMSTER; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MONONUCLEAR CELL; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD20; CELL LINE, TUMOR; CHO CELLS; COMPLEMENT C1Q; CRICETINAE; CRICETULUS; FEMALE; GLYCOPEPTIDES; GLYCOSIDE HYDROLASES; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOSACCHARIDES; PEPTIDE-N4-(N-ACETYL-BETA-GLUCOSAMINYL) ASPARAGINE AMIDASE; PROTEIN BINDING; RECEPTORS, FC; RECEPTORS, IGG;

EID: 84951291802     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.11.027     Document Type: Article

References (26)

1. Albert H., Collin M., Dudziak D., Ravetch J.V., Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. USA 2008, 105:15005-15009.
2. Allhorn M., Olin A.I., Nimmerjahn F., Collin M. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS ONE 2008, 3:e1413.
3. Allhorn M., Briceño J.G., Baudino L., Lood C., Olsson M.L., Izui S., Collin M. The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood 2010, 115:5080-5088.
4. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
5. Beck A., Wagner-Rousset E., Bussat M.C., Lokteff M., Klinguer-Hamour C., Haeuw J.F., Goetsch L., Wurch T., Van Dorsselaer A., Corvaïa N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 2008, 9:482-501.
6. Biburger M., Aschermann S., Schwab I., Lux A., Albert H., Danzer H., Woigk M., Dudziak D., Nimmerjahn F. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011, 35:932-944.
7. Collin M., Shannon O., Björck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc. Natl. Acad. Sci. USA 2008, 105:4265-4270.
8. Glennie M.J., van de Winkel J.G. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 2003, 8:503-510.
9. Jung S.T., Reddy S.T., Kang T.H., Borrok M.J., Sandlie I., Tucker P.W., Georgiou G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. USA 2010, 107:604-609.
10. Lim S.H., Beers S.A., French R.R., Johnson P.W., Glennie M.J., Cragg M.S. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010, 95:135-143.
11. Lux A., Yu X., Scanlan C.N., Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J. Immunol. 2013, 190:4315-4323.
12. Lux A., Seeling M., Baerenwaldt A., Lehmann B., Schwab I., Repp R., Meidenbauer N., Mackensen A., Hartmann A., Heidkamp G., et al. A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep. 2014, 7:236-248.
13. Meyer S., Leusen J.H., Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 2014, 6:1133-1144.
14. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
15. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24:19-28.
16. Nimmerjahn F., Ravetch J.V. Analyzing antibody-Fc-receptor interactions. Methods Mol. Biol. 2008, 415:151-162.
17. Pincetic A., Bournazos S., DiLillo D.J., Maamary J., Wang T.T., Dahan R., Fiebiger B.M., Ravetch J.V. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 2014, 15:707-716.
18. Pound J.D., Lund J., Jefferis R. Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. Mol. Immunol. 1993, 30:233-241.
19. Racila E., Link B.K., Weng W.K., Witzig T.E., Ansell S., Maurer M.J., Huang J., Dahle C., Halwani A., Levy R., Weiner G.J. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 2008, 14:6697-6703.
20. Ruuls S.R., Lammerts van Bueren J.J., van de Winkel J.G., Parren P.W. Novel human antibody therapeutics: the age of the Umabs. Biotechnol. J. 2008, 3:1157-1171.
21. Sazinsky S.L., Ott R.G., Silver N.W., Tidor B., Ravetch J.V., Wittrup K.D. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. USA 2008, 105:20167-20172.
22. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 2013, 13:176-189.
23. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278:3466-3473.
24. Subedi G.P., Barb A.W. The structural role of antibody N-glycosylation in receptor interactions. Structure 2015, 23:1573-1583.
25. Wang S.Y., Veeramani S., Racila E., Cagley J., Fritzinger D.C., Vogel C.W., St John W., Weiner G.J. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009, 114:5322-5330.
26. Yamaguchi Y., Nishimura M., Nagano M., Yagi H., Sasakawa H., Uchida K., Shitara K., Kato K. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim. Biophys. Acta 2006, 1760:693-700.